GPX2

Across TCGA pan-cancer cohorts, GPX2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated GPX2 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GPX2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GPX2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where GPX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.905	0.783	.009	44	view →
CCRCC	OS	Median	II,III,IV	1.000	0.380	.002	38	view →
LUAD	OS	Tertile	III,IV	0.210	0.679	.010	19	view →
UCEC	OS	Tertile	III,IV	0.345	1.000	.018	8	view →
COAD	DFS	Quartile	All	1.000	0.829	.035	6	view →
HNSC	OS	Tertile	All	0.632	0.856	.004	6	view →
LSCC	DFS	Quartile	All	0.863	0.592	.025	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

GPX2–PDAC (OS)

Open the PDAC breakdown →